Hofseth BioCare ASA (OB: HBC)
Health Care · Biotechnology · NO
Nkr1.37
+1.86% today · -29.0% 1Y
Hofseth BioCare ASA (OB: HBC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $75.51M and employs 81 people.
Over the last twelve months the share price has lost 29.0%, trading between 1.10 and 2.42.
Tweenvest scores Hofseth BioCare ASA across four factors: quality 25/100, value 59/100, growth 100/100. Its strongest factor is growth.
HBC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $75.51M
- Revenue (TTM)
- $24.45M
- P/E
- —
- EPS
- -0.34
- Dividend yield
- —
- Beta (5Y)
- 0.26
- 52-week high
- Nkr2.42
- 52-week low
- Nkr1.10
- Avg volume (3M)
- —
- Shares outstanding
- 522.24M
- Employees
- 81
- Next earnings
- —
About Hofseth BioCare ASA
Hofseth BioCare ASA, an international firm based in Norway, specializes in developing and supplying premium biomarine ingredients for both human and animal health. The company's product portfolio features various specialized offerings, including Brilliant salmon oil and OmeGo salmon oil, which promotes healthy cholesterol levels and supports cardiovascular well-being. ProGo, a salmon protein hydrolysate, serves as a rapidly assimilated protein supplement. For skeletal and joint health, Hofseth offers CalGo, a marine calcium powder. CollaGo, a collagen peptide powder, is designed to improve the appearance of hair, skin, and nails. Additionally, PetGo provides a non-soluble protein formulation. Distribution of these products is managed through a multi-channel approach, utilizing a network of distributors, agents, and its dedicated internal sales team. Hofseth BioCare also holds a significant research collaboration with Stanford University School of Medicine, focusing on pre-clinical and clinical studies related to conditions such as necrotizing enterocolitis and irritable bowel syndrome. Established in 2000, the company's main operations are based in Ålesund, Norway.
- ISIN
- NO0010598683
- Founded
- 2000
- Listed since
- Dec 2, 2011
- Exchange
- Oslo Bors
- Currency
- NOK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.